Daptomycin

Overview

A reminder that peptides are not a fringe category — this is a frontline hospital antibiotic for MRSA bacteraemia, and it is a lipopeptide. It also carries one of the most instructive failures in antibiotic history: it does not work in the lungs, for a specific and knowable reason.

How it works

The calcium-dependent lipid tail inserts into the Gram-positive bacterial membrane, oligomerises, and causes rapid membrane depolarisation and potassium efflux. The cell dies without lysis, which reduces the release of inflammatory cell-wall fragments compared with lytic antibiotics.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• Randomized non-inferiority trials plus two decades of hospital use.
• The negative pneumonia trial is as important as the positive ones.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Effective against MRSA bacteraemia Strong evidence

  Non-inferior to standard therapy in a randomized trial, and a mainstay option when vancomycin fails or cannot be used.

• Rapid bactericidal activity Strong evidence

  Concentration-dependent killing, generally faster than vancomycin in vitro.

• Once-daily dosing Strong evidence

  Practical for outpatient parenteral antibiotic therapy.

• Non-lytic killing Moderate evidence

  Avoids the inflammatory burst associated with cell-wall-lysing agents.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Inactivated by pulmonary surfactant — useless in pneumonia Serious

  Its pneumonia trial failed because surfactant neutralises the drug in the alveolus. It must never be used for pneumonia, and this is a mechanism-level absolute.

• Rhabdomyolysis and myopathy Serious

  Creatine kinase must be monitored at least weekly; the drug is stopped if CK rises with muscle symptoms.

• Eosinophilic pneumonia Serious

  A distinct, serious hypersensitivity reaction that paradoxically affects the lungs, typically after 2 or more weeks of therapy.

• Peripheral neuropathy Moderate evidence

  Reported with prolonged therapy.

• Statin interaction Moderate evidence

  Concurrent statins compound muscle toxicity risk; many clinicians hold the statin during therapy.

• Resistance emergence on therapy Moderate evidence

  Non-susceptibility can develop during treatment of deep-seated infection, particularly with inadequate source control.

Who should avoid it

• Pneumonia — inactivated by surfactant
• Known daptomycin hypersensitivity
• Caution with concurrent statin therapy

If used under medical supervision, monitor

• Creatine kinase at least weekly, more often with statins or renal impairment
• Renal function for dose adjustment
• New dyspnoea or fever after 2+ weeks — consider eosinophilic pneumonia
• Repeat blood cultures in bacteraemia

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• HMG-CoA reductase inhibitors (statins) — additive myopathy risk
• Tobramycin — increases daptomycin exposure
• Warfarin — monitor INR in the first days

Regulatory & legal status

Prescription antibiotic administered in hospital or outpatient parenteral settings.

Infographic

Daptomycin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Daptomycin
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Antimicrobial & Antibiotic